ReviewPharmacology & therapeutics2017
Potential role of CYP1B1 in the development and treatment of metabolic diseases.
Review in Pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 214 citations in OpenAlex.
- Genome-wide CRISPR screen reveals CGS-15943 induced heme-dependent cell death mediated by aryl hydrocarbon receptor in lung cancer cells.Apoptosis : an international journal on programmed cell death · 2026Article
- Integrated genomic, transcriptomic, and microsomal metabolic profiling of cytochrome P450s in squirrels.The Journal of veterinary medical science · 2026Article
- Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells.British journal of clinical pharmacology · 2026Article
- The role of Zearalenone in epigenetic modifications of candidate genes in Nellore heifers.Tropical animal health and production · 2026Article
- CYP1B1 modulates stress and repair pathways in airway cells challenged by wood smoke particles.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Integrated machine learning and multi-omics analysis identifies CYP1B1 as a candidate target of orientin in intervertebral disc degeneration-associated low back pain.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Identification and characterization of tryptophan metabolism-related genes in carotid artery plaques.PloS one · 2026Article
- Zearalenone exposure may increase the risk of non-alcoholic fatty liver disease by activating CYP1B1-SCD1.Current research in toxicology · 2026Article
- Role of central and peripheral serotonin in liver physiology and diseases.Theranostics · 2026Review
- CYP1B1- and CYP1A1-Template systems and their application to metabolism and inhibition.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2025Article
- Article
- Utilising bioinformatics and molecular docking technology to explore the underlying mechanisms of intervertebral disc degeneration with potential therapeutic drugs and formulas.Journal of global health · 2025Article
- Human intestinal fungus Clavispora lusitaniae attenuates colitis through Pyruvate decarboxylase-derived Indole-3-ethanol.Nature communications · 2025Article
- Expression and Clinical Significance of Cytochrome 1B1 in Bone Sarcomas.Pharmaceuticals (Basel, Switzerland) · 2025Article
- CYP1B1 Mediates Cigarette Smoke-Induced Lipid Accumulation in Alveolar Type 2 Cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Effects of Crocus sativus and its active constituents on cytochrome P450: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Proanthocyanidins inhibit CYP1B1 through mixed-type kinetics and stable binding in molecular dynamics simulations.Scientific reports · 2025Article
- Phytochemical profiling, antioxidant properties, and anticancer activity of Pourouma cecropiifolia Mart. from the Ecuadorian Amazon.NPJ science of food · 2025Article
- Protein-Level Analysis of Differential Response to Chemotherapy in Triple-Negative Breast Cancer Identifies CYP1B1 as a Biomarker for Chemotherapy Resistance.Cancer research communications · 2025Article
- Obesity alters the fitness of peritumoral adipose tissue, exacerbating tumor invasiveness in renal cancer through the induction of ADAM12 and CYP1B1.Molecular oncology · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Cytochrome P450 1B1 (CYP1B1), a member of CYP superfamily, is expressed in liver and extrahepatic tissues carries out the metabolism of numerous xenobiotics, including metabolic activation of polycyclic aromatic hydrocarbons. Surprisingly, CYP1B1 was also shown to be important in regulating endogenous metabolic pathways, including the metabolism of steroid hormones, fatty acids, melatonin, and vitamins. CYP1B1 and nuclear receptors including peroxisome proliferator-activated receptors (PPARs), estrogen receptor (ER), and retinoic acid receptors (RAR) contribute to the maintenance of the homeostasis of these endogenous compounds. Many natural flavonoids and synthetic stilbenes show inhibitory activity toward CYP1B1 expression and function, notably isorhamnetin and 2,4,3',5'-tetramethoxystilbene. Accumulating evidence indicates that modulation of CYP1B1 can decrease adipogenesis and tumorigenesis, and prevent obesity, hypertension, atherosclerosis, and cancer. Therefore, it may be feasible to consider CYP1B1 as a therapeutic target for the treatment of metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.